Exercise and Nutrition Intervention in Ovarian Cancer

NCT ID: NCT06250686

Last Updated: 2024-02-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

185 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-10

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this multicenter randomized controlled trial is to compare a 6-month exercise and nutrition intervention (intervention group, IG) aimed at maintaining or improving physical functioning and quality of life with usual care (control group, CG) in ovarian cancer patients.

The main question it aims to answer is:

• Can an exercise and nutrition program improve physical performance during and after active treatment for ovarian cancer?

Participants of the IG will undergo:

* Weeks 1-18: approximately 15-30 minutes of daily exercise (cardio, resistance, and balance exercises); nutritional counseling focusing on malnutrition (protein-energy malnutrition).
* Weeks 19-25: More intense daily training; nutritional counseling focusing on the Mediterranean diet.

The study design includes 3 survey time points:

* Baseline: After surgery and before starting chemotherapy
* T1: After chemotherapy (week 19)
* T2: After intervention (week 26)

The primary outcome is:

• 6-minute walk test, 6 months after enrollment (T2)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer Malnutrition Muscle Wasting Fatigue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

usual care

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention

6 month exercise and nutrition intervention

Group Type EXPERIMENTAL

combined exercise and nutrition intervention

Intervention Type BEHAVIORAL

Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

combined exercise and nutrition intervention

Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with FIGO II-IV stage ovarian, fallopian tube, or peritoneal carcinoma
* Patients must be treated with surgery and chemotherapy
* Patients receiving adjuvant or neoadjuvant chemotherapy but not yet started

Exclusion Criteria

* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status greater than 2
* Patients with inadequate German language skills
* Patients with physical or mental impairments that make it impossible to perform the training programs or study procedures
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Charite University, Berlin, Germany

OTHER

Sponsor Role collaborator

University Hospital Dresden

OTHER

Sponsor Role collaborator

Kliniken Essen-Mitte

OTHER

Sponsor Role collaborator

University Hospital Tuebingen

OTHER

Sponsor Role collaborator

University Hospital Schleswig-Holstein

OTHER

Sponsor Role collaborator

Technical University of Munich

OTHER

Sponsor Role collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Holger Schulz, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Hamburg-Eppendorf

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charité Universitätsmedizin Berlin

Berlin, , Germany

Site Status RECRUITING

Universitätskrebszentrum Dresden

Dresden, , Germany

Site Status NOT_YET_RECRUITING

Evang. Klinik Essen-Mitte

Essen, , Germany

Site Status RECRUITING

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status RECRUITING

Universitätsklinikum Schleswig-Holstein

Kiel, , Germany

Site Status NOT_YET_RECRUITING

Klinikum rechts der Isar der Technischen Universität München Ismaniger Straße 22

München, , Germany

Site Status NOT_YET_RECRUITING

Universitätsklinikum Tübingen

Tübingen, , Germany

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Holger Schulz, Prof. Dr.

Role: CONTACT

+49 (0) 40 7410 56806

Tabea Maurer, Dr.

Role: CONTACT

+49 (0) 40 7410 50800

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jalid Sehouli, Prof. Dr.

Role: primary

Pauline Wimberger, Prof. Dr.

Role: primary

Philipp Harter, PD Dr.

Role: primary

Barbara Schmalfeldt, Prof. Dr.

Role: primary

Nicolai Maass, Prof. Dr.

Role: primary

Marion Kiechle, Prof. Dr.

Role: primary

Stefan Kommoss, Prof. Dr.

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Maurer T, Belau MH, Zyriax BC, Welsch G, Jagemann B, Chang-Claude J, Daubmann A, Buchholz A, Glismann K, Moeller A, Sehouli J, Woopen H, Wimberger P, Harter P, Kaiser S, Maass N, Kiechle M, Engler T, Schmalfeldt B, Schulz H. Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial. BMC Cancer. 2024 Nov 11;24(1):1379. doi: 10.1186/s12885-024-13102-y.

Reference Type DERIVED
PMID: 39528997 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BENITA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Activity and Cancer Survivorship Exercise Pilot
NCT07283029 ACTIVE_NOT_RECRUITING NA
Effectiveness of a Cancer Exercise Program
NCT06039488 ENROLLING_BY_INVITATION NA